December 20, 2021 News by Marta Figueiredo, PhD NICE Still Opposes Adding Fampyra to NHS for England The National Institute for Health and Care Excellence (NICE) in England is set to again recommend against adding Fampyra (fampridine) to the list of medications available to multiple sclerosis (MS) patients with walking difficulties through the countryās national health service (NHS). The poor cost-effectiveness of Fampyra ā sold…
April 16, 2020 News by Mary Chapman Fampyra, Aid for Walking, Favored for Inclusion in NHS Scotland After being rejected twice in the last four years, Fampyra (fampridine; marketed as Ampyra in the U.S.) is now being recommended by the Scottish Medicines ConsortiumĀ (SMC) for use in the country’sĀ National Health System (NHS) to treat walking disabilities in adults withĀ multiple sclerosis (MS). Scotland…
November 19, 2018 News by Ana Pena PhD MS Therapy Fampyra Again Not Recommended for Use in Scottish National Health System The Scottish Medicines Consortium (SMC) issued a negative recommendation on the use of Fampyra (fampridine; marketed as Ampyra in the U.S.) in the National Health System (NHS), for the…
February 8, 2018 News by Alice MelĆ£o, MSc #ACTRIMS2018 – Ampyra Also Aids Cognition, Use of Extremities in MS Patients Ampyra (dalfampridine), approved to treat walking difficulties in multiple sclerosis (MS) patients, also helps with cognition and movement in the upper and lower extremities, according to a recent scientific presentation. These findings were reported at the 3rd Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018Ā in…
November 20, 2017 News by Iqra Mumal, MSc Fampyra/Ampyra May Improve Walking Speed in MS Patients Over Longer Term, Study Says Available long-term data on Fampyra (fampridine;Ā 4-aminopyridine)Ā suggest the treatment may improve walking speed in patients with multiple sclerosis (MS) for up to one year, but more research is needed, a French study reports. The study āMultiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Reviewā…
May 25, 2017 News by Patricia Silva, PhD Fampyra Granted Standard Approval in Europe as Trial Results Support Effectiveness Fampyra (prolonged-release fampridine tablets) ā sold in the U.S. as Ampyra (dalfampridine) ā has now been granted standard marketing authorization in Europe. The approval was based on the results of a Biogen-sponsored Phase 3 clinical trial confirming the drugās safety and efficacy in improving walking in patients with multiple…
April 10, 2017 News by Patricia Inacio, PhD Ampyra Aided Walking in PPMS and RMS Patients Over Long Term, Neurologist Says in Interview AmpyraĀ (dalfampridine) shows long-term efficacy in improving walking ability in peopleĀ with multiple sclerosis, according to a study evaluating the treatment’s use in progressive and relapsing MS patients over two years. The study, āMonitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis,ā was published in the…
April 10, 2017 News by Patricia Inacio, PhD Transcript of Interview on Ampyra Research, MS Walking Ability and Long-Term Use Multiple Sclerosis News Today interviewedĀ Dr. Linard Filli,āØ an MS researcher at the University Hospital ZurichĀ involved in clinical studies of prolonged release Ampyra (dalfampridine), on walking ability in MS patients,Ā and Dr. Andrew Blight, chief scientific officer at Acorda Therapeutics, the treatment’s developer. Here is a full transcript of that interview.Ā An…
November 11, 2016 News by Joana Fernandes, PhD Ampyra/Fampyra for MS Patients ‘Not Recommended’ by NHS Scotland Despite recent studies showing that treatment with Ampyra (Fampyra in Europe; fampridine) improves both walking speed and ability, and offers psychological benefits to patients with multiple sclerosis (MS), the Scottish Medicines Consortium (SMC)Ā recently decided to not recommend the drug for use on the National Health Service (NHS) in Scotland.
September 20, 2016 News by Patricia Inacio, PhD #ECTRIMS2016 – MS Patients Achieve Sustained Improvements in Mobility with Ampyra A recent study showed that the clinical benefits offered by Ampyra (fampridine) in improving mobility among multiple sclerosis (MS) patients hasĀ clinical significance. The results were shown in an oral presentation, āSustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study,ā atĀ the European Committee for…